Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Day (September 2023)
115 slides from Staar Surgical's investor day presentation, Sep 14, 2023
Slide 1: STAAR Surgical Vision 2026 Investor Day
STAAR Surgical VISION 2026 STAAR Surgical Investor Day September14,2023 NASDAQ:STAA
Slide 2: Agenda
Agenda Time EDT Topic Speaker 8:30 a.m. Welcome/Safe Harbor Brian Moore, Investor Relations Vision 2026: Achieving STAAR’s Global Growth Opportunity Tom Frinzi, Chair of the Board and CEO Extending EVO ICL’s Leadership Position Magda Michna, PhD Chief Clinical, Regulatory and Medical Affairs Officer
Slide 3: Forward Looking Statements and Non-GAAP Financial Measures
Forward Looking Statements and Non-GAAP Financial Measures All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023
Slide 4: Vision 2026: Achieving STAAR's Global Growth Opportunity
VISION 2026 Achieving STAAR’s Global Growth Opportunity TOM FRINZI Chair of the Board and CEO STAAR Surgical Company STAAR SURGICAL 04
Slide 5: Vision 2026 / Exciting Global Growth
Vision 2026 / Exciting Global Growth The first Choice for Doctors and Patients Seeking Visual Freedom STAAR SURGICAL 05
Slide 6: Vision 2026 / Growth Foundation
Vision 2026 / Growth Foundation 1 Invest in Largest Market Opportunities 2 Drive EVO ICL Awareness 3 Enhance Surgeon Support and Education 4 Introduce New Products 5 Create a High Performance Organization STAAR SURGICAL 06
Slide 7: Vision 2026 / Double-Digit Sales CAGR
Vision 2026 / Double-Digit Sales CAGR Approximately 15% TO Approximately 20% ANNUAL GROWTH RANGE Y/Y 3-Year Sales CAGR (2024-2026) Approximately 15% Approximately $500 To $550 MILLION Fiscal 2026 Sales TARGET SALES MODEL STAAR SURGICAL 07
Slide 8: Our History of 15%+ Global ICL Sales Growth
Select Growth Markets (3-Year CAGR, 2020-2022) Our History of 15%+ Global ICL Sales Growth CANADA +20% NETHERLANDS +19% KOREA +24% BELGIUM +15% UNITED STATES +28% ITALY +21% CHINA +32% JAPAN +40 FRANCE +28% HONG KONG +27% EGYPT +26% INDIA +19% MEXICO +16% THAILAND +59% MALAYSIA +31% VIETNAM +18% SIN
Slide 9: Our Large Market Opportunity: Global Myopia Epidemic
Our Large Market Opportunity Global Myopia Epidemic Today: Every third person in the world 2050: Every other person in the world * Normal Myopia Billions of People Myopia High Myopia 6.0 5.0 4.0 3.0 2.0 1.0 0.0 4.9 4.1 3.4 2.6 2.0 1.4 2000 2010 2020 2030 2040 2050 *BHVI, adapted from Holden et al. 2
Slide 10: Non-Surgical Myopia Correction Options
Non-Surgical Myopia Correction Options Myopia Management May reduce, but does not eliminate Myopia Glasses Limits certain activities and lifestyles Contact Lenses May cause dry eyes STAAR SURGICAL 10
Slide 11: Surgical Myopia Correction Options
Surgical Myopia Correction Options Laser Vision Correction in Decline Refractive Procedures Laser Vision Correction (LASIK, PRK, SMILE) Lens-Based (EVO ICL) 2009 Japan Laser Vision Correction Procedures Down From 2008 Peak 75% U.S. Laser Vision Correction Procedures Down From 2008 Peak 50% 2022 LASI
Slide 12: 7D STAARSURGICAL
7D STAARSURGICAL
Slide 13: Investing in the Largest Markets
Achieving STAAR’s Global Growth Opportunity Investing in the Largest Markets Top 15 Refractive Procedure Markets China U.S. 34% 17% of 4.5M Estimated of 4.5M Estimated Procedures in Procedures in 2023 2023 Top 15 Markets 83% of 4.5 Estimated Procedures in 2023 U.S. 764,183 South Korea 250,073 India
Slide 14: Investing in Fastest Growing Markets
Achieving STAAR’s Global Growth Opportunity Investing in Fastest Growing Markets 2024E-2026E China U.S. ROW India South Korea Japan +462,441 Expected Procedure Growth Global Procedures expected to grow from 4.5M to 5.0M* *Market Scope STAAR Custom Model, August 23, 2023. 349,573 56,406 45,523 30,047
Slide 15: Milestone Sales Achievements
Milestone Sales Achievements TOTAL ICLs SOLD… STAAR expects to sell more 1M 2M 3M 6M ICLs in the next three years 1999 2Q19 2Q22 1Q24E 4Q26E (2024 2026) than the first 25 years of ICL sales combined. 20 YEARS 3 YEARS < 2 YEARS VISION 2026 STAAR SURGICAL 15
Slide 16: Robust Product Pipeline
Robust Product Pipeline Presbyopia EVO VIVA™ Sphere and Toric Injectors ACCUJECT Ordering System STELLA EVO+CHINA Next Gen EVO Internal R&D and Partnerships STAAR SURGICAL 16
Slide 17: Creating a High Performance Organization
Creating a High Performance Organization VISION Exciting Global Growth The first Choice for Doctors and Patients Seeking Visual Freedom Corporate Values Voice of Customer Voice of Employees Facts and Data Driven Organizaion VITAL FEW PROJECTS AND INVESTMENTS THE ORGANIZATION STRUCTURE & TEAM TO EXEC
Slide 18: The STAAR Team / Up Next
The STAAR Team / Up Next… STAAR’s Proprietary EVO ICL Technology Robust Product Pipeline Increasing Surgeon Support and Education Continuing EVO ICL’s Global Growth APAC, EMEA, Americas Driving EVO ICL Awareness Commercial Initiatives to Accelerate Growth Operational Excellence and Scale to Sell Mil
Slide 19: Extending EVO ICL's Leadership Position
VISION 2026 Extending EVO ICL’s Leadership Position MAGDA MICHNA, PHD Chief Clinical, Regulatory and Medical Affairs Officer STAAR Surgical Company STAAR SURGICAL 19
Slide 20: The Collamer Difference
The Collamer® Difference Robust Product Pipeline Surgeon Support and Education 01 02 03 STAAR SURGICAL 20
Slide 21: EVO ICL – The Collamer Difference
EVO ICL – The Collamer® Difference Collamer® Collamer is a proprietary lens material created and used exclusively by STAAR®. The Collamer material is bonded with UV absorbing chromophore into a copolymer that offers UV protection. Collagen Collagen is the main structural protein in the extracellular
Slide 22: The EVO ICL Advantage: A Disruptive Technology
The EVO ICL Advantage: A Disruptive Technology 22 Sharp, clearvision No removal of corneal tissue Bio-Compatible Quiet in the Eye Excellent vision at night Does not cause dry eye syndrome Quick procedure and recovery Removable by a surgeon Protection from UV rays Additive Company Logo
Slide 23: Only One Phakic IOL Is Collamer
Only One Phakic Intraocular Lens (IOL) Is Collamer EVO ICL – Posterior Chamber / Collamer Other Phakic IOLs Posterior chamber the narrow space behind the iris Cachet Lens – Anterior Chamber / Acrylic and in front of the natural crystalline lens Due to concerns about endothelial cells loss in a group
Slide 24: STAAR Listens: The Voice of Our Global Customers
STAAR Listens The Voice of Our Global Customers Current State 93% Global Surgeon Willingness to Recommend (N=907, April 13, 2023) Two Survey Questions What do you recommend STAAR do to increase your adoption of our ICLs? If STAAR could improve one or two important things, what would you recommend?”
Slide 25: Robust Product Pipeline
Robust Product Pipeline Presbyopia EVOVIVA™ Sphere and Toric Injectors ACCUJECT Ordering System STELLA EVO+ CHINA Next Gen EVO Internal R&D and Partnerships Company Logo
Slide 26: Product Pipeline: Presbyopia EVO VIVA
Product Pipeline: Presbyopia EVO VIVA EVO VIVA™ is an extended depth of focus (EDoF) lens Surgeon training and education on lens and patient selection are critical variables for success Expands EVO ICL family of lenses to early presbyopes ages 45-55 Removable and saves crystalline lens Expanded comm
Slide 27: Product Pipeline: Lens Delivery Devices
Product Pipeline: Lens Delivery Devices ACCUJECT Injector System Voice of customer Partnered w/ Medicel – a global leader in injector systems Custom designed injector system for EVO/EVO+ ICLs Launch strategy begins in US then global expansion PHASE 1 User Loaded Injector 2024 PHASE 2 Pre-loaded Inje
Slide 28: Product Pipeline: ICL Planning and Ordering System Stella
Product Pipeline: ICL Planning and Ordering System Stella Optimized User Interface and Workflow Patient Management Intuitive Calculator Order Management Inventory / Lens Reservations Upgrade replacement for OCOS online calculator and ordering system Significant time savings for customers estimated a
Slide 29: Product Pipeline: EVO+ ICL in China
Product Pipeline: A New Lens for the World’s Largest Refractive Market EVO+ ICL in China Expanded optic lenses for patients with larger pupils Allows customer segmentation TARGET 2025 Company Logo 29
Slide 30: Product Pipeline: Next Generation EVO Lenses
Product Pipeline Next Generation EVO Lenses Internal R&D + partnerships to develop next generation EVO ICL Intermediate Lens Sizes Collamer 2.0 Customized lenses Company Logo 30
Slide 31: Surgeon Support and Education
Surgeon Support and Education Benchmark and leverage international expertise to support surgeon journey in the US Peer to Peer Peer to Peer Medical Education Medical Investigator Knowledge Education Programs Publications Initiated Trials Sharing staar surgical 31
Slide 32: China: Durable Growth in the Largest Refractive Market Globally
CHINA: Durable Growth in the Largest Refractive Market Globally ZHENG WANG, MD Aier Eye Hospital Group Shanghai, China STAAR SURGICAL 32
Slide 33: Refractive Surgery in China – the Big Data
Refractive Surgery in China–the Big Data Wang Zheng, MD EYE Aier EVO ICL International Summit EYE AIER EYE HOSPITAL STAAR SURGICAL The 2 nd Aier EVO ICL International Summit
Slide 34: Myopia: The Present Situation
EVO ICL Aier EVO ICL International Summit Myopia: The Present Situation EYE AIER EYE HOSPITAL STAAR SURGICAL Myopia prevalence in Asia is higher than Europe and US. China has reached 48.5%, the highest prevalence of myopia in Asia Race (Tay‘s）All Ages Chinese 48.5% Eurasian 34.7% Indians 30.4% Malay
Slide 35: Refractive Surgery Penetration Rate
EVO ICL Aier EVO ICL International Summit EYE AIER EYE HOSPITAL STAAR SURGICAL Refractive Surgery Penetration Rate Myopia prevalence in Asia is higher than Europe and US. While LVC per 1k population in China is only 0.7 while Western Europe reached 1.3 and USA 2.6. Market Scope: 2021 Refractive Surg
Slide 36: Big Data Report in Aier Group
EVO ICL Aier EVO ICL International Summit EYE AIER EYE HOSPITAL STAAR SURGICAL Big Data Report in Aier Group Research Period 2018-2021 Research Population Refractive surgery patients in Aier China and Clínica Baviera Research Data Valid Data 1,830,981 eyes/ 931,071 patients Research Region Mainland
Slide 37: EVO ICL Surgical Volume
EVO ICL Aier EVO ICL International Summit EYE AIER EYE HOSPITAL STAAR SURGICAL EVO ICL The 2 nd Aier EVO ICL International Summit Surgical Volume 700,000 600,000 500,000 400,000 300,000 200,000 100,000 2018 2019 611,920 311,935 250,099 61,836 407,874 340,122 67,752 499,252 433,677 65,575 526,503 85,
Slide 38: Seasonality Trends
EVO ICL Aier EVO ICL International Summit EYE AIER EYE HOSPITAL STAAR SURGICAL EVO ICL The 2 nd Aier EVO ICL International Summit Seasonality Trends Aier China Aier Europe 1月 2月 3月 4月 5月 6月 7月 8月 9月 10月 11月 12月 1月 2月 3月 4月 5月 6月 7月 8月 9月 10月 11月 12月 Jan. Feb. March April May June July Aug. Sept. Oct
Slide 39: Patient Age
EVO ICL Aier EVO ICL International Summit EYE AIER EYE HOSPITAL STAAR SURGICAL EVO ICL The 2 nd Aier EVO ICL International Summit Patient Age Average Age＞ 40 y/o Aier China 25.5 3.6% Aier Europe 33.3 21.7% Percentage of Patient Age >40 8 6.7 6 3.8 3.2 3.0 4 % 2 0 First-tier cities New first-tier cit
Slide 40: Gender
EVO ICL Aier EVO ICL International Summit EYE AIER EYE HOSPITAL STAAR SURGICAL EVO ICL The 2 nd Aier EVO ICL International Summit Gender Male Female Aier China 57.5% 42.5% Aier Europe 49.7%50.3% Aier China Aier Europe 77.7 22.3 76.4 23.7 34.8 65.2 27.6 72.4 29.0 71.0 36.3 63.7 41.6 58.5 41.2 58.8 57
Slide 41: Degree of Refractive Error
Aier EVO ICL International Summit Degree of Refractive Error EYE AIER EYE HOSPITAL STAAR® SURGICAL Low Myopia (below -3D) Moderate Myopia (-3 to -6D) High Myopia (-6 to -10D) Extreme Myopia (above -10D) Aier China 13.3% 53.7% 29.8% 3.1% Aier Europe (Clinica Baviera) 40.1% 41.0% 11.6% 1.3% EVO ICL Th
Slide 42: Growth of ICL Volume in Aier Group
Aier EVO ICL International Summit Growth ICL Volume in Aier Group EYE AIER EYE HOSPITAL STAAR® SURGICAL 2014 2015 2016 2017 2018 2019 2020 2021 2022 Approval of V4c (EVO) 36% 68% 85% 82% 45% 31% 22% 17% CAGR in the past 4 years: LVC: 18.6% ICL: 28.0% EVO ICL The 2 nd Aier EVO ICL International Summi
Slide 43: Surgery Type
Aier EVO ICL International Summit Surgery Type EYE AIER EYE HOSPITAL STAAR® SURGICAL Year Low Myopia (below -3D) Moderate Myopia (-3 to -6D) High Myopia (-6 to -10D) Extreme Myopia (above -10D) NO.1 NO.2 NO.1 NO.2 NO.1 NO.2 NO.1 NO.2 2021 SMILE 46.6% LASIK 46.2% SMILE 46.8% LASIK 45.4% LASIK 52.8% I
Slide 44: ICL Trends
Aier EVO ICL International Summit ICL Trends EYE AIER EYE HOSPITAL STAAR® SURGICAL Year Low to moderate myopic ICL surgery 2021 2.9% 2018 1.5% ICL CGAR（Y2018-Y2021） 31.23% 57.69% 0% 10% 20% 30% 40% 50% 60% 70% 1 st & 2 nd tier cities 3 rd & 4 th tier cities First and second-tier cities ICL Portion,
Slide 45: UCVA on Day 1
UCVAonDay1 81.79% (80.88%in2018-2020) UCDA(post-op) ≥BCVA(pre-op) ICL87.6% LASIK85.7% SMILE78.4%
Slide 46: Surgical Outcomes (ICL)
Surgical Outcomes (ICL) UCVA 100 87.6 94.4 95.9 96.1 96.0 93.5 proportion（%）80 60 40 20 0 1 Day 1 Week 1 Month 3 Months 6 Months 12 Months
Slide 47: Refractive Stability
Refractive Stability ICL LASIK SMILE Pre-op -8.49D -5.11D -4.49D Post-op 1M -0.00D 0.07D 0.01D Post-op 12M -0.12D -0.09D -0.10D 2 0 -2 -4 -6 -8 -10 pre-operation -4.49 -5.11 -8.49 0.01 1month -0.01 -0.04 -0.09 0.12 3 months 12 ICL LASIK SMILE months
Slide 48: Aier Study of ICL on Low to Moderate Myopia
Aier Study of ICL on Low to Moderate Myopia • 731 Consecutive eyes which also suitable for LVC • 5 centers • Age 18-50 y/o (mean, 25.5±6.0) • Preop MRSE: -5.23±1.27D – Sphere -4.56±1.25D, Cylinder 1.27±1.17D • Preop CDVA: 1.0 or better • Target refraction: Plano • 447 non-toric • 284 toric (cyl >0.7
Slide 49: Efficacy & Predictability
Efficacy & Predictability MRSE: 93.98% 100.00% • Preop -5.23±1.27D (-6.0 to 0.75) 80.00% • Postop: +0.13±0.13D (-0.63 to 0.50) 60.00% ±0.50D 99.31% 40.00% ±1.00D 100% 20.00% 0.00% 0.34% 4.99% 0.34% 0.34% 0.00% 0.00% 2yearspostop Chart
Slide 50: Postop Cylinder Distribution
Postop Cylinder Distribution • Preop: 1.27±1.17D (0 to 4.50) • Postop: 0.25±0.25D (0 to 0.75) 100 All Eyes 50 % 0 0 to 0.25D 0.26 to 0.50 0.51 to 1.00 >1.01D DD 100 80 60 40 20 0 <0.25 <0.50 <1.00 <1.50 2yearspostop
Slide 51: Efficacy & Safety
Efficacy & Safety 术前 BCVA Postop UCVA Postop UCVA Preop BCVA 100.0% 4.6% 95.4% 71.7% 29.4% 99.6% 99.0% 99.0% 99.7% 100% 100% 90% 90% 80% 80% 70% 70% 60% 60% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% ＜ 1.0 ≥1.0 ≥1.2 ≥1.5 ≥1.5 ≥1 ≥0.8 ≥0.6 ≥0.5 0.0% 88.1% 96.2% 29.4% 95.6%
Slide 52: Efficacy & Safety
Efficacy & Safety 100% 80% 60% 40% 20% 0% 0.1% Postop UCVA vs. preop BCVA 较 44.6% 32.8% 20.7% 1.7% 2Y Postop UCVA vs Preop BCVA -2lines-1line+1line+2linesequal +2lines-2lines-1line+1lineunchanged Efficacy Index 1.25 Safety Index 1.23 0.0%0.9% 15.0% 61.4% 22.8% 00.20.40.60.81 术较 BCVAchanges-2lines-1l
Slide 53: Visual Quality
Visual Quality Qualityofvisioncomparison-0.100.10.20.30.40.50.6PreopPostopPreopPostopRMShcomasphericalICLSMILE
Slide 54: Scatter
ScatterICLLASIKSMILEPreopOSIPostopOSI1.00.70.30.60.71.9ICLLASIKSMILEPreopOSIPostopOSI1.00.70.30.60.71.9
Slide 55: Safety Parameters
SafetyParameters IOP (mmHg) 0 5 10 15 IOP preop 1D 1W 1M 3M 6M 12M 0 200 400 800 1000 150-1100 64-1200 149-1260 130-1030 100-1160 110-1040 1D 1W 1M 3M 6M 12M Vault ECD 2000 2200 2400 2600 2800 3000 3200 preop 1M 12M -3.4% Stable IOP, vault, and endothelial cell density Wide variance in vaulting
Slide 56: Complications
Complications • No vision threatening complications • Improper sizing requiring ICL exchange 1.37% –ICL oversize: 6/731 (0.8%) –ICL undersize: 4/731 (0.5%) • Cataract: 0% Bar graph
Slide 57: Summary
Summary • The refractive surgery market in China is far from saturation • There’re some interesting characteristics of Chinese market • The surgical results are good and still improving in Aier hospitals • ICL is very promising in low and moderate myopic eyes Company Logo
Slide 58: Thank you
=VrI 2m Ft STAAR_ EY 248% “D SURGICAL Thank you...
Slide 59: Q&A Session
a Q&A Session 1 —— “2D STAARSURGICAL i)
Slide 60: 15-Minute Break
15-MinuteBreakCompany Logo
Slide 61: U.S. Refractive Market: From LASIK to Lens-Based
61 U. S. REFRACTIVEMARKET: From LASIK to Lens-Based STEPHEN SLADE, MD Slade & Baker Vision Houston, TX STAARSURGICAL
Slide 62: EVO: Technology, Surgeon, Patient
EVO: Technology, Surgeon, Patient Stephen G. Slade MD, FACS September 14, 2023 Alcon, J&J, B&L, STAAR, Apple, Novartis, RxSight, CorneaGen, Vialase, Luminex Glaukos, EyeBrain, Surgilum, Occumetrics, LensTec, Allotex, Omega Ophthalmics, Presbyopia Therapies
Slide 63: Early Adoption Timeline: LASIK and ICL
-1991 First LASIK in US -1996 FDA Lasik Approval – 2005 FDA ICL Approval -Courses, Papers, Texts Early Adoption
Slide 64: Picking Winners
Picking Winners Is it unique, elegant? Do I believe in the product? Do I want this for my patients? Does it meet an unmet need, commercial potential?
Slide 65: Lesson Learned from LASIK: UCVA Drives Satisfaction
Lesson Learned from LASIK: UCVA Drives Satisfaction Schallhorn, AECOS 2016 UCVA 20/X40 67% 58% 46% 40% 33% 29% 36% 42% 41% 40% 4% 6% 12% 19% 27% 0% 20% 40% 60% 80% 100% 12.5 16 20 25 40 Very Satisfied Satisfied Dissatisfied or Neither N=12,936 20/
Slide 66: Post UCVA Equal To Or Better Than Pre
Post UCVA Equal To Or Better Than Pre % of Cases *Targeted For Emmetropia (± 0.5D) BSCVA 0 10 20 30 40 50 60 60% 55% 59% 47% 56% 58% 1wk 1mo.3mos.6mos.12mos. 52% 24mos. 36 mos.
Slide 67: Stability
97% 99% 99% 99% 99% 98% 98% 99% 100% 80% Stability 60% 40% 100% 20% 80% 0% Preop 1wk 1mo 3mos 6mos 12 mos 24 mo 60% 40% 20% 0% Preop 7.0 6.0 5.0 4.0 3.0 Additive 2.0 1.0 0.0 Preop 1Wk 1Mo 3Mos 6Mos 12Mos 24Mos 36Mos 1wk 1mo 3mos 6mos 12mos 24mos 36mos 0% 81% 85%86%85%85% 83%81% 8.0 9.0 10.0 11.0 12.
Slide 68: Surgeon's Perspective
Surgeon’s Perspective Fast, straightforward procedure Not dose dependent Plays well with others Office OR?
Slide 69: Patient's Perspective
Patient’s Perspective! Wow Factor Average 20/30 at 1 hour Not visible, Removable Intact, No large incision Elective Surgery
Slide 70: Thank you!
Thank you!
Slide 71: Establishing EVO ICL as The First Choice for Doctors and Patients
Image VISION 2026 Establishing EVO ICL as The First Choice for Doctors and Patients WARREN FOUST Chief Operating Officer STAAR Surgical Company STAAR SURGICAL 71
Slide 72: EVO ICL Global Growth
01 EVO ICL Global Growth Driving EVO ICL Awareness 02 03 Commercial initiatives to Accelerate Growth 04 Operational Excellence and Scale to Sell Millions of EVOs Annually STAAR SURGICAL 72
Slide 73: EVO ICL TM ICL China STAAR SURGICAL
EVO ICL TM ICL China STAAR SURGICAL
Slide 74: APAC: Broad-based Geographic Growth and Share Gains
APAC: STAAR is Achieving Broad-based Geographic Growth and Share Gains Bar Graph ICL Sales by Country Refractive Procedure Market Share, 2022 $ Millions China Japan South Korea Rest of APAC 250.00 200.00 150.00 100.00 50.00 2018 2019 2020 2021 2022 CHINA JAPAN SOUTH KOREA ~20% ~50% ~15% Growth Varia
Slide 75: EMEA: Progress Despite Macroeconomic Headwinds
EMEA: Progress Despite Macroeconomic Headwinds Bar Graph ICL Sales by Country Refractive Procedure Market Share, 2022 $ Millions Spain Germany Great Britain European Distributors SPAIN GERMANY ~15% ~8% Growth Variables Economic weakness 9% Distributor vs. Direct EMEA Level of STAAR investment Sales
Slide 76: Americas: Opportunity Abounds
Americas: Opportunity Abounds ICL Sales by Country $ Millions United States Canada Latin America 25.00 20.00 15.00 10.00 5.00 – 2018 2019 2020 2021 2022 Refractive Procedure Market Share, 2022 22% Americas UNITED STATES < 5% Sales CAGR (2018-2022) Growth Variables Myopia prevalence Level of STAAR in
Slide 77: Driving EVO ICL Awareness, Our Marketing Works
Driving EVO ICL Awareness, Our Marketing Works... STAAR SURGICAL 77
Slide 78: Will Levis hos EVO ICL lenses. STAAR SURGICAL EVOICL
Will Levis hos EVO ICL lenses. STAAR SURGICAL EVOICL
Slide 79: Building Consumer Trust in EVO Safety and Efficacy
Building Consumer Trust in EVO Safety and Efficacy Partnership includes: Joe & Kevin Jonas 36 Stop Tour sponsorship, Chose EVO ICL EVO ICL video ad played before every concert 8+ social posts on @JoeJonas, @KevinJonas, and @JonasBrothers social accounts (IG, TT, FB, TW) Reaching their 80M social med
Slide 80: Kevin + Joe Jonas Upgrade Their Vision
KEVIN+ JOE JONAS upgrade their vision KEVIN+ JOE JONAS upgrade their vision
Slide 81: Impact of Investments in EVO ICL Awareness and Digital Marketing
Impact of Investments in EVO ICL Awareness and Digital Marketing Delivering Unique Visitors to U.S. Doctor Finder (EVOICL.com) Joe Jonas Campaign Launch 343,996 628,556 647,221 995,389 1,879,577 1,660,986 83,212 266,279 318,608 179,529 343,996 628,556 Q1 '22 v '21 Q2 '22 v '21 Q3 '22 v '21 Q4 '22 v
Slide 82: Impact of Investments: Past Six Quarters
Impact of Investments in EVO ICL Awareness and Digital Marketing - Past Six Quarters vs. Prior Year Period Significant Increase in U.S. Doctor Finder Searches Joe Jonas Campaign Launch 2,517 19,404 18,824 24,705 16,662 31,644 10,288 123,959 19,404 194,765 24,705 205,155 1Q21 v. 1Q22 2Q21 v. 2Q22 3Q2
Slide 83: EVO ICL Patient Journey is Too Often Incomplete
Marketing investments EVO ICL Patient Journey is Too Often Incomplete (Current) Discovery / Awareness Research / Interest Inquiry Action DIGITAL MARKETING Social Media ads Display ads YouTube / CTV ads Native ads Audio-only platforms ads SEM/SEO Public Relations ORGANIC SOCIAL MEDIA: EVO WEBSITE SCH
Slide 84: Process Improvements + Commercial Initiatives
Process Improvements + Commercial Initiatives staar surgical EVOicl 84
Slide 85: Partnering with Call Center to Complete Patient Discovery
Commercial Initiative Partnering with Best-In-Class Call Center to Complete EVO ICL Patient Discovery Discovery / Awareness Research / Interest Inquiry Action DIGITAL MARKETING Social Media ads Display ads YouTube / CTV ads Native ads Audio-only platforms ads SEM/SEO Public Relations ORGANIC SOCIAL
Slide 86: Increasing Knowledge of STAAR's Customers to Optimize Segmentation
Commercial Initiative Increasing Knowledge of STAAR’s Customers to Optimize Segmentation GOAL: Best serve meet/exceed each unique customer’s needs and drive EVO ICL utilization U.S. EVO ICL Customers 400+ Practices 600+ Surgeons 300K+ $450M+ Annual U.S. Refractive Procedures U.S. Refractive Procedur
Slide 87: Drive EVO ICL Adoption
Drive EVO ICL Adoption PRE-OPERATIVE Eye measurement and lens size selection INTRA-OPERATIVE Surgery POST-OPERATIVE Patient follow-up and understanding outcomes Territory Manager Practice Development Clinical Applications Specialist STAAR recently established a structure and foundation for a World C
Slide 88: Executing U.S. Pilots with Significant EVO ICL Growth Commitments
Commercial Initiative Executing U.S. Pilots with Significant EVO ICL Growth Commitments Pilots Tailored for the U.S. Refractive Market MARKET SHARE OF QUALIFIED PATIENTS OBS CONSTRUCTION/ DEVELOPMENT New Ways to Partner with Our Customers EQUIPMENT/ PROCUREMENT The number of pilots, pace of learning
Slide 89: Operational Excellence and Scale
Operational Excellence and Scale ... staar surgical EVOicl 89
Slide 90: Delivering Our Lenses to Surgeons and Patients Faster in 2023
Operational Excellence We Are Delivering Our Lenses to Surgeons and Patients Faster in 2023 SERVICE LEVEL Spheric ~100% Toric 81% TORIC MADE TO ORDER LENSES (MTO) Number of Open MTO Lenses Change from January 11, 2023 to August 31, 2023 60% Days Outstanding MTO Lenses 13% 87% 81% 19% Outstanding 0 t
Slide 91: Existing and Planned Capacity
91 Existing and Planned Capacity Manufacturing Capacity to Support $800M+ Annual Sales Existing and Planned through 2026 Capacity Expansion Monrovia, CA UNITS DOLLARS @$525/UNIT 600,000 800,000 1,200,000 1,600,000 1,600,000 2022 2023E 2024E 2025E 2026E $315,000,000 $420,000,000 $630,000,000 $840,000
Slide 92: Happy EVO ICL Patients and Surgeons!
Happy EVO ICL Patients and Surgeons!
Slide 93: Surgeon Panel: The Global EVO ICL Experience
Surgeon Panel: The Global EVO ICL Experience SCOTT D. BARNES, MD Chief Medical Officer STAAR Surgical (Moderator) ZHENG WANG, MD Aier Eye Hospital Group FRANK KERKOFF, MD FYEO Medical BLAKE WILLIAMSON, MD Williamson Eye Center STEPHEN SLADE, MD Slade & Baker Vision ROGER ZALDIVAR, MD Instituto Zaldi
Slide 94: 15-Minute Break
15-Minute Break 15-Minute Break STAAR SURGICAL
Slide 95: Long Term Plan and Value Creation
95 VISION 2026 Long Term Planand Value Creation PATRICK WILLIAMS Chief Financial Officer STAAR Surgical Company STAAR SURGICAL
Slide 96: STAAR's Financial Strength
96 01 02 03 STAAR’s Financial Strength Target Sales and Operating Model Financial Discipline STAAR SURGICAL
Slide 97: Fiscal 2023 Outlook
97 Fiscal 2023 Outlook 3Q23 Sales Approximately $80M FY23 Sales Approximately $320M $325M FY23 Gross Margin Approximately 78% FY23 CapEx Approximately $26M STAAR SURGICAL
Slide 98: We Know You Have Many Investment Choices
98 We Know You Have Many Investment Choices Small and Mid Cap Public Company Universe Market Caps $300M to $10 Billion All Sectors N = 2771 Healthcare Sector N=394 STAAR SURGICAL
Slide 99: We Know You Have Many Investment Choices
99 We Know You Have Many Investment Choices Small and Mid Cap Public Company Universe Market Caps $300M to $10 Billion ALL All Sectors N = 2771 Healthcare Sector N = 394 Positive GAAP Earnings All Sectors N = 1665 60% Healthcare Sector N = 95 24% STAAR SURGICAL
Slide 100: We Know You Have Many Investment Choices
100 We Know You Have Many Investment Choices Small and Mid Cap Public Company Universe Market Caps $300M to $10 Billion ALL All Sectors N = 2771 Healthcare Sector N = 394 Positive GAAP Earnings All Sectors N = 1665 60% Healthcare Sector N = 95 24% 15% Sales Growth Consensus All Sectors N = 171 6% He
Slide 101: All Roads Lead to STAAR
All Roads Lead to STAAR All Sectors NASDAQ: STAA Healthcare Sector N = 171 N=19 101 6% 5% Staar surgical Staar surgical
Slide 102: Vision 2026 / Double-Digit Sales CAGR
Vision 2026 / Double-Digit Sales Cagr Approximately 15% To Approximately 20% An Nu Al Gro Wt H Ran Ge Y /Y 3-Year Sales Cagr (2024-2026) Approximately $500 To $550 Million Fiscal 2026 Sales 102 Target Sales Model Staar Surgical
Slide 103: Target Operating Model – Sales Sensitivities 2024-2026
Target operating model – sales sensitivities 2024-2026 apac 15% to 20% 3-year cagr china ~20% emea 10% to 15% 3-year cagr americas 25% to 30% 3-year cagr u.s. 30% to 50% pace of evo icl adoption down the diopter curve (evo icl owning -6d and above refractive vision correction) country mix (direct vs
Slide 104: Vision 2026 / Double-Digit GAAP Operating Margin
Vision 2026 / Double-Digit GAAP Operating Margin Approximately Approximately TO 12% 16% ANNUAL OPERATING MARGIN GAAP OPERATING MARGIN (2024 2026) Approximately $60 TO $90 MILLION TARGET OPERATING MARGIN Fiscal 2026 Operating Income 104 Staar Surgical
Slide 105: Target Operating Model – Additional Details
Vision 2026 / Target Operating Model – Additional Details 15% Sales Growth CAGR Scenario through FY2026E + ~$180M + ~700bps Sales $ Growth Operating Margin Expansion FY 2023 Outlook FY 2026E Change From FY23 Outlook FY 2026E Change From FY23 Outlook Growth Scenario 15% CAGR 20% CAGR Sales $323M $500
Slide 106: STAAR Demonstrates Strong Sales Growth
STAAR Demonstrates Strong Sales Growth (in millions) $101 $129 $141 $213 $270 $323 500 $550 Growth Inflection + Year 1 GAAP Profitability Temporary COVID-19 Impact Vision 2026 2018 2019 2020 2021 2022 2023 Outlook 2024E 2025E 2026E 106 Staar Surgical
Slide 107: STAAR Knows How to Expand Operating Margin
STAAR Knows How to Expand Operating Margin Vision 2026 16% 12% 15% 15% 8% 5% 5% 4% 2017 % 2018 2019 2020 2021 2022 2023 Outlook 2024E 2025E 2026E (4%) * Initial sales outlook provided prior to COVID on January 13, 2020, was for sales mid-point of $177 million or +18% Y/Y Growth for 2020. CAGR of 28%
Slide 108: STAAR Knows How to Generate Cash
STAAR Knows How to Generate Cash (in millions) ADJUSTED EBITDA EX. SBC BALANCE SHEET CASH CapEx Expected to be approximately $20-$30M Annually $226 $200 75 $110 $153 $120 $104 $67 $61 $50 $26 $23 $16 $19 2018 2019 2020 2021 2022 2023 Outlook 2024E 2025E 2026E 2017 2018 2019 2020 2021 2022 * Initial
Slide 109: Target Sales and Operating Margin
TARGET SALES AND OPERATING MARGIN Profitable & 15%+SalesGrowthTop5% Staar Surgical SALES Approximately 15% to Approximately 20% ANNUAL GROWTH RANGE Y / Y 3-Year Sales CAGR (2024-2026) Approximately $500 TO $550 MILLION Fiscal 2026 Sales OPERATING MARGIN Approximately 12% to 16% ANNUAL OPERATING MARG
Slide 110: Closing Remarks
Closing Remarks TOM FRINZI Chair of the Board and CEO STAAR Surgical Company 110 Staar Surgical
Slide 111: Closing Remarks: Evergreen and Refreshed Priorities
Closing Remarks TOM FRINZI Chair of the Board and CEO STAAR Surgical Company 110 Staar Surgical Evergreen and Refreshed as Data and Voice of Customer Dictates… 01 Increase surgeon support and education 2023 02 Presbyopia (Viva™) 2023 03 Faster production/Increased capacity to deliver our lenses to c
Slide 112: STAAR is a Global Growth Company
Select Growth Markets (3-Year CAGR, 2020-2022) STAAR is a Global Growth Company CANADA +20% NETHERLANDS +19% KOREA +24% BELGIUM +15% UNITED STATES +28 ITALY +22% CHINA +32% JAPAN +40% FRANCE +28% HONG KONG +27% EGYPT +26% INDIA +19% THAILAND +59% MALAYSIA +31% MEXICO +16% SINGAPORE +60% VIETNAM +18%
Slide 113: Emerging Markets and Rapidly Growing Middle Class and Wealthy
Emerging Markets and Rapidly Growing Middle Class and Wealthy STAAR Will Also Invest in the Next Stages of Growth UNITED STATES 340 Million Population CHINA 1.4 Billion Population INDIA 1.4 Billion Population MEXICO 128 Million Population BRAZIL 216 Million Population INDONESIA 278 Million Populatio
Slide 114: Planning for Billion Dollar Annual Sales Milestone Post 2026
Planning for Billion Dollar Annual Sales Milestone Post 2026 Project Roadrunner Will Ultimately Support $1B+ Annual Sales CapEx through 2026 fully captured in 3-Year plan Phased additional Arizona manufacturing allows over $1 Billion Annual Sales TARGET 2028 114 Staar Surgical
Slide 115: It's Our Time… It's EVO's Time!
Vision 2026 IT’S OUR TIME… IT’S EVO’S TIME! Staar Surgical